Results 211 to 220 of about 10,758 (225)

Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockers

European Journal of Cancer
Immune checkpoint blockers (ICBs) can induce immune-related adverse events (irAEs) whose management is based on expert opinion and may require the prescription of steroids and/or immunosuppressants (ISs). Recent data suggest that these treatments can reduce the effectiveness of ICBs.To investigate the relationship between the use of steroids and/or ISs
Emilie Routier, Jean-Marie Michot
exaly   +3 more sources

Dupilumab for the treatment of immune checkpoint blockers' induced pruritus

Journal of the European Academy of Dermatology and Venereology, 2023
Evdoxia Panou, Flora Stavridi, Christos Nikolaou, Alexander Stratigos, Vasiliki Nikolaou   +4 more
openaire   +2 more sources

Methotrexate in the treatment of immune checkpoint blocker-induced bullous pemphigoid

European Journal of Cancer, 2021
Connie R, Shi, Tracey S, Otto, Leah L, Thompson, Michael S, Chang, Kerry L, Reynolds, Steven T, Chen   +5 more
openaire   +2 more sources

Clinical toxicology of immune checkpoint blockers

Toxicology Letters, 2021
openaire   +1 more source

Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias

Cancer Treatment Reviews, 2022
Maria Kfoury, Matthieu Texier, Jean-Marie Michot   +2 more
exaly  

Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs

European Journal of Cancer, 2022
Christophe Massard, Capucine Baldini, Samy Ammari   +2 more
exaly  

The effect of concomitant use of statins, NSAIDs, low-dose aspirin, metformin and beta-blockers on outcomes in patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis

OncoImmunology, 2021
Jinglong Chen
exaly  

Novel evidence for the prognostic impact of β-blockers in solid cancer patients receiving immune checkpoint inhibitors

International Immunopharmacology, 2022
Siyuan Zhu
exaly  

Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models

Proceedings of the National Academy of Sciences of the United States of America, 2023
Meenal Datta, , Kamila Naxerova
exaly  

Integration of gold nanodendrites and immune checkpoint blockers to achieve highly efficient photothermal immunotherapy for eradicating primary and distant metastatic osteosarcoma

Materials Today Nano, 2022
Guanping He, Xiaoyu Pan, Chuanbin Mao
exaly